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Background: Skin tests for neuromuscular blocking agents (NMBAs) are not currently recommended for
the general population undergoing general anaesthesia. In a previous study we have reported a high
incidence of positive allergy tests for NMBAs in patients with a positive history of non-anaesthetic drug
allergy, a larger prospective study being needed to conﬁrm those preliminary results. The objective of
this study was to compare the skin tests results for patients with a positive history of antibiotic-induced
immediate type hypersensitivity reactions to those of controls without drug allergies.
Methods: Ninety eight patients with previous antibiotic hypersensitivity and 72 controls were pro-
spectively included. Skin tests were performed for atracurium, pancuronium, rocuronium, and
suxamethonium.
Results: We found 65 positive skin tests from the 392 tests performed in patients with a positive history
of antibiotic hypersensitivity (1 6.58%) and 23 positive skin tests from the 288 performed in controls
(7.98%), the two incidences showing signiﬁcant statistical difference (p ¼ 0.0011). The relative risk for
having a positive skin test for NMBAs for patients versus controls was 1.77 (1.15e2.76). For atracurium,
skin tests were more often positive in patients with a positive history of antibiotic hypersensitivity versus
controls (p ¼ 0.02). For pancuronium, rocuronium and suxamethonium the statistical difference was not
attained (p-values 0.08 for pancuronium, 0.23 for rocuronium, and 0.26 for suxamethonium).
Conclusions: Patients with a positive history of antibiotic hypersensitivity seem to have a higher inci-
dence of positive skin tests for NMBAs. They might represent a group at higher risk for developing
intraoperative anaphylaxis compared to the general population.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The identiﬁcation of risk factors for drug hypersensitivity may
deﬁne categories of patients who are at risk after drug exposure
and may allow the avoidance of certain drugs in patients with
previous sensitization by performing an appropriate allergological
screening. Current epidemiological studies indicate both exposure
characteristics, host and drug factors, including sex, age and
possibly atopy, as representing such risk factors, though there is no
deﬁnitive consensus regarding some of them.1,2
Neuromuscular blocking agents (NMBAs) are the drugs most
often incriminated in intraanaesthetic anaphylaxis. Allergologicala and Intensive Care, Clinical
3-5, Cluj-Napoca, Romania.
u).
ety of Allergology.
rgology. Production and hosting by Elseskin tests for NMBAs are not currently recommended for the gen-
eral population undergoing general anaesthesia.3e5 However, in a
previous study we have reported a high prevalence of positive
in vivo and in vitro allergy tests for NMBAs in patients with a pos-
itive history of non-anaesthetic drug allergy and hypothesized that
preoperative testing for NMBAsmight be necessary in this category
of patients.6 Screening tests for anaesthetic drugs might prove
valuable when a deﬁned risk proﬁle is selected, larger prospective
studies being needed to conﬁrm those preliminary results and
validate changes in clinical anaesthesiology and allergology
practice.6
The objective of the study was to compare the skin tests results
for a high number of patients with a positive history of antibiotic-
induced hypersensitivity reactions to those of controls without
previous drug allergies and to establish whether antibiotic hyper-
sensitivity and atopy are risk factors for positive skin tests to
NMBAs.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
N. Hagau et al. / Allergology International 65 (2016) 52e55 53Methods
The study was approved by the Ethics Committee of the Uni-
versity of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca
(no.6/2008). We included in this prospective study 98 consecu-
tive patients with previous signs and symptoms suggestive for
antibiotic-induced immediate-type hypersensitivity reactions
ranging from urticaria, angioedema, and bronchospasm, to severe
hypotension or cardiac arrest. The patients were referred to the
allergy unit for testing by the general practitioners or anaesthesi-
ologists as they required to undergo elective surgery under general
anaesthesia. Each patient completed, guided by an allergologist, a
structured questionnaire containing data regarding the date of the
clinical reactions, the signs and symptoms, current medication and
comorbidities. All patients presented positive skin tests for the
culprit antibiotics (either the skin prick test or the intradermal test).
A number of 72 healthy controls, people without any previous drug
hypersensitivity, nor positive skin tests, were included as well.
Exclusion criteria were: a positive history of hypersensitivity to
drugs others than antibiotics, treatment with steroids or antihis-
tamines, dermographism and pregnancy. All patients and controls
were informed verbally and in written about the study and signed
the informed consent form.
Skin tests included the skin prick test (SPT) and the intradermal
test (IDT) and were performed according to international recom-
mendations for atracurium (Tracrium®, Glaxo-Smith-Kline, Great
Britain), pancuronium (Pavulon®, Organon, Holland), rocuronium
(Esmeron®, Organon, Holland), and suxamethonium (Lysthenon®,
Nycomed, Austria) for each patient and control. The allergologist
was blinded regarding the patients' hypersensitivity history. We
used 1% histamine as positive control and 0.9% NaCl as negative
controls. The skin tests were performed using commercially avail-
able drug solutions for intravenous use, which were diluted with
0.9% NaCl to obtain the currently recommended dilutions for
testing (Table 1).7e9 The skin tests were performed on the anterior
region of the forearm. For the SPT, a drop of the drug solution was
placed and the skinwas pricked with a prick needle in the centre of
the drop. For the IDT, 0.02e0.03 mL of drug solution was injected
using a 29.5 gauge needle, producing a 4 mm injection wheal. The
SPT was considered positive when the wheal diameter was 3 mm
at 20 min, while the IDT was considered positive if the reading
wheal (RW) doubled the injection wheal (IW) at 20 min (the RW/
IW ratio 2).7,9 First, the SPT was performed. When the SPT wasTable 1
Maximal non-reactive NMBAs concentrations used for the skin tests.
NMBA Undiluted drug (mg/mL) SPT
Dilution
Atracurium 10 1/10
Pancuronium 2 Undiluted
Rocuronium 10 Undiluted
Suxamethonium 50 1/5
NMBA, neuromuscular blocking agent; SPT, skin prick test; IDT, intradermal test.
Table 2
Skin test results for NMBAs.
No.
patients
No. tests Atopic disease
Patients with positive history 98 392 Present (N ¼ 20)
Absent (N ¼ 78)
Controls 72 288 Present (N ¼ 37)
Absent (N ¼ 35)
SPT, skin prick test; IDT, intradermal test; No, number.negative, the IDT was performed subsequently and if the SPT was
positive, the IDT was not performed. The skin test result was
considered positive when either the SPT or the IDT were positive,
and negative when neither of these were positive.
The atopic phenotype status was recorded according to the
patients' report of previous atopic diseases like allergic rhinitis with
nasal symptoms, allergic asthma, acute and chronic urticaria and/or
atopic dermatitis.
Chi square tests and Fisher exact test were used to assess the
differences between categorial data. Relative risk was calculated as
a/(a þ b)/c/(c þ d), where a ¼ number of patients with previous
antibiotic hypersensitivity with positive skin tests for NMBAs,
b ¼ number of patients with previous antibiotic hypersensitivity
and negative skin tests for NMBAs, c ¼ number of controls with
positive skin tests for NMBAs, and d ¼ number of controls with
negative skin tests for NMBAs.
Results
A total of 98 patients with previous antibiotic-induced imme-
diate type hypersensitivity reactions were tested using the SPT and
the IDT for atracurium, rocuronium, pancuronium and sux-
amethonium, thus we performed 392 tests for NMBAs. The culprit
antibiotics were penicillins in 83 patients (84.69%): penicillin in 37
patients, ampicillin in 18, amoxicillin in 13, oxacillin in 1, piper-
acillin in 1 and two or more penicillins in 14 patients. In the
remaining 15 patients (15.30%), the culprit drugs were cephalo-
sporins in 5 patients (cefaclor 1, ceftriaxone 1 and cefuroxime 3
patients), trimetroprim-sulphametoxazole in 1 patient, quinolones
in 6 patients, metronidazole in one and erythromycin in one pa-
tient. All patients presented positive skin tests for the culprit drugs.
We also tested 72 healthy controls without previous drug-induced
immediate-type hypersensitivity reactions for the same NMBAs,
which represents a total of 288 tests performed in controls. From
the 392 skin tests performed in patients with antibiotic hyper-
sensitivity, we found 9 positive SPT and 56 positive IDT in 46 out of
the 98 patients (46.93%). From the 288 skin tests performed in
controls, we found 23 positive IDT in 19 out of the 72 healthy
controls (26.38%). Thus, we found 65 positive skin tests from the
392 tests performed in patients with a positive history of antibiotic
hypersensitivity (16.58%) and 23 positive skin tests from the 288
performed in controls (7.98%), the two incidences showing signif-
icant statistical difference (Chi squared test, p ¼ 0.0011) (Table 2).IDT
Concentration (mg/mL) Dilution Concentration (mg/mL)
1 1/1000 10
2 1/10 200
10 1/100 100
10 1/500 100
Atracurium Pancuronium Rocuronium Suxamethonium
SPT IDT SPT IDT SPT IDT SPT IDT
1/20 6/19 1/20 3/19 0/20 2/20 2/20 1/18
4/78 28/74 0/78 4/78 1/78 12/77 0/78 0/78
0/37 14/37 0/37 1/37 0/37 3/37 0/37 0/37
0/35 2/35 0/35 0/35 0/35 3/35 0/35 0/35
N. Hagau et al. / Allergology International 65 (2016) 52e5554The relative risk for having a positive skin test for NMBAs for pa-
tients versus controls was 1.77 (95%CI: 1.15e2.76).
When each NMBA was considered, for atracurium, skin tests
were more often positive in patients with a positive history of
antibiotic hypersensitivity when compared to controls (Fisher test,
p¼ 0.02), while for pancuronium, rocuronium and suxamethonium
the statistical difference was not attained (Fisher test, p-values 0.08
for pancuronium, 0.23 for rocuronium, and 0.26 for sux-
amethonium). From the four tested NMBAs, the highest number of
positive skin tests was observed for atracurium (Table 2).
From the 98 patients, 9 had previously undergone surgery under
general anaesthesia using NMBAs, with no adverse reactions. Four
patients from these presented positive skin tests for NMBAs. Eleven
controls, from which 3 with demonstrating positive skin tests for
NMBAs, had previous uneventful exposure to NMBAs during gen-
eral anaesthesia.
After testing, all the patients underwent surgery under general
anaesthesia using the NMBAs for which the skin tests were nega-
tive. Anaesthesia was uneventful in all subjects by avoiding the
NMBAs for which the skin test was positive in the patients with
positive skin tests. None of the patients with previous antibiotic-
induced hypersensitivity reactions presented positive skin tests
for all the tested NMBAs.
From the 98 patients (82 female and 16 male patients), 20
(20.40%) declared having an atopic phenotype. From the 72 con-
trols, 37 declared having an atopic phenotype. Thus, we tested 57
subjects with atopy and 113 subjects without atopy. We performed
a total number of 228 skin tests in subjects (patients with previous
antibiotic hypersensitivity and controls) that presented in the his-
tory atopic diseases, with 34 of them having positive skin tests
results (14.91%). For those without atopic disease, we performed a
total number of 452 skin tests for NMBAs, 54 of them being positive
(11.94%). There is no statistical difference between those with and
without atopic disease regarding the positivity of the skin tests'
results (Chi square, p ¼ 0.28).
From the 130 females tested, a number of 51 (39.23%) presented
positive skin tests for NMBAs, while from the 40 males tested, a
number of 14 (35%) presented positive skin tests for NMBAs (Chi
square, p ¼ 0.087).
Discussion
Both drug and host factors, including sex, age, and genetic
predisposition, together with characteristics of the drug exposure,
interact in the development of drug allergy.1 The performance of
screening testsmight be justiﬁed for well-deﬁned at-risk categories
of patients for which certain drugs could be avoided.
NMBAs are the leading drugs responsible for immediate hy-
persensitivity reactions during anaesthesia, but there is no
demonstrated evidence supporting systematic pre-operative
screening in the general population at this time.3 Skin tests
should not be used to screen for drug allergy in the absence of
clinical history compatible with allergy.4,8,10,11
Although there is no demonstrated evidence for systematic pre-
operative screening in the general population, well-deﬁned at-risk
patients might beneﬁt from the performance of screening tests.3 In
the past, some authors stipulated that there is no evidence of
increased risk of anaphylaxis to NMBAs in patients who have had
anaphylaxis to drugs not used in the operating theatre and in pa-
tients presenting atopic disease.12 However, there have been pre-
vious reports showing a high prevalence of skin tests for NMBAs in
patients with other drug-induced immediate-type hypersensitivity
reactions.13,14 Similarly, we have previously reported a high prev-
alence of positive in vivo and in vitro tests for NMBAs in patients
with a positive history of non-anaesthetic drug-inducedimmediate-type hypersensitivity reactions and larger, prospective
studies are needed.6
In drug allergy, skin testing is the most widely used method to
determine sensitization, as other tests are less sensitive and less
speciﬁc.8 In this study we found that the patients with a positive
history of antibiotic hypersensitivity have a higher risk to present a
positive skin tests for NMBAs when screening skin tests are per-
formed. Positive skin tests might be the result of sensitization, local
histamine release or the use of irritative drug concentrations for
skin testing.
The fact that some of the healthy controls also presented posi-
tive skin tests can be argumented by the occurrence of latent
sensitization after exposure to cross-reactive compounds. Sensiti-
zation may be caused by previous exposure to foods, cosmetics,
disinfectants and industrial materials containing quaternary
substituted ammonium ions in their structure.3
Moreover, we found different positivity rates for the four NMBAs
we tested. The highest number of positive skin tests was observed
for atracurium, a drug known to cause direct local histamine release
when skin tests are performed. The maximal nonreactive concen-
trations for IDT need to be adequately deﬁned for anaesthetic
drugs.15e17 False positive results might be avoided by the use of
adequately deﬁned testing concentrations as some of the NMBAs
cause local histamine release.8,10 For atracurium, the high incidence
of positive intradermal tests might be related to increased local
histamine release or suggests that the recommended test doses
might be too high.
A limitation of our study is the fact that the positive predictive
value of skin tests with NMBAs is unknown.18 A positive skin test
does not mean that the patient is going to develop allergic reactions
upon exposure. The progression from a positive allergy test to
clinical allergy is multifactorial, and the presence of a positive skin
test might be a proof of latent sensitization, with possible sub-
clinical, minor or major clinical reaction.19 The prevalence of latent
sensitization to NMBAs (skin tests and drug speciﬁc IgE dosing) was
shown to vary between 1.6% in subjects without atopy or a drug
allergy history to 16% in subjects with these risk factors.19 Sensiti-
zation might be a necessary preliminary condition for anaphylaxis
to appear clinically and patients with latent sensitization, assessed
here by allergological skin tests, might represent a group of patients
at high risk for developing intraanaesthetic anaphylaxis due to
exposure to NMBAs. Patients with a positive history of antibiotic-
induced immediate type hypersensitivity reactions might repre-
sent a group at higher risk for developing intraoperative anaphy-
laxis compared to the general population. This risk can not yet be
evaluated as the predictive value of positive skin tests results is
unknown.
There is no deﬁnitive agreement whether the presence of the
atopic phenotype is a risk factor for drug hypersensitivity in gen-
eral.1,2,10,20 In our patients, the presence of the atopic phenotype
was not demonstrated as being a risk factor for having a positive
skin test to NMBAs. Our study reinforces other epidemiological data
on self-reported drug-induced hypersensitivity reactions, which
are more often in females.2 However, we concluded that gender per
se is not a risk factor for positive skin tests for NMBAs.
In conclusion, a positive history of antibiotic-induced immedi-
ate type hypersensitivity is predictive for positive skin tests for
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